Product Detail
Dolutegravir-d3
Dolutegravir Stable Isotopes
Stock Status: In Stock
Login to view price
Live
For Research & Analytical Purposes. Not for Personal use.
Category
Stable Isotopes
API Family
Dolutegravir
Storage
Store at refrigerator (2-8°C) for long term storage
Hazard Information
Refer MSDS for accurate information.
Dolutegravir-d3 Product Information
Dolutegravir-d3 is listed under Stable Isotopes. It is associated with Dolutegravir and is intended for analytical research, quality control and pharmaceutical reference standard applications. The product is supplied by Clearsynth under CAT No. CS-O-03645.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight, stock enquiry details and supporting documentation.
Technical Data
Product Name
Dolutegravir-d3
CAS No.
1051375-16-6 (Unlabeled)
CAT No.
CS-O-03645
Molecular Formula
C₂₀H₁₆D₃F₂N₃O₅
Molecular Weight
422.40
Category
API Family
Storage Condition
Store at refrigerator (2-8°C) for long term storage
SMILES
O=C1C(N(C=C2C(NC([2H])([2H])C3=C(C([2H])=C(C=C3)F)F)=O)C[C@@]4([H])N1[C@@H](CCO4)C)=C(O)C2=O
IUPAC Name
(4R,12aS)-N-((2,4-difluorophenyl-3-d)methyl-d2)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
Purity by HPLC
Not less than 90 %
Hazard Compound
Refer MSDS for accurate information.
Description
Overview
"Dolutegravir Stable Isotope; Dolutegravir Deuterated, Intended for use as an internal standard for the quantification of Dolutegravir by GC- or LC-mass spectrometry."
Synonyms
(4R,12aS)-N-((2,4-difluorophenyl-3-d)methyl-d2)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
Application Notes
"Dolutegravir Stable Isotope; Dolutegravir Deuterated, Intended for use as an internal standard for the quantification of Dolutegravir by GC- or LC-mass spectrometry."
References
"Kobayashi; M, et al, Antimicrob Agents Chemother,; 55; 813 (2011); Garrido; C, et al,: Antiviral; Res,; 90; 164 (2011); Lenz; J,C,C, et al,: Exp, Opin, Invest, Drugs; 20; 537 (2011);"
